Evidence based evaluation of the intervention of Qingxin Jieyu Formula in patients with enhanced inflammatory response in non-ST-segment elevated myocardial infarctio

Not Applicable

Not yet recruiting

• Conditions: non-ST-segment elevated myocardial infarction

• Registration Number: ITMCTR2024000066
• Lead Sponsor: Xiyuan Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2024-05-29

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1)35 years = age =75 years
2)The diagnostic criteria of non-ST-segment elevation myocardial infarction were met
3)The syndrome differentiation of TCM belongs to the syndrome of stasis and toxin
4)hs-CRP=2mg/L
5)Volunteer and sign the informed consent form

Exclusion Criteria

Subjects will be excluded from the study if they meet any of the following criteria:

Presence of primary cardiomyopathy, infective endocarditis, or other heart diseases not caused by coronary artery lesions.
Recent history (within the past month) of infection, fever, trauma, burns, or surgery.
Tendency to bleed or a reduced platelet count.
Current use of antibiotics or traditional Chinese medicine for clearing heat and detoxifying.
Severe heart failure with a left ventricular ejection fraction of less than 50%.
Individuals with severe cardiac arrhythmias (paroxysmal ventricular tachycardia) who have experienced recent recurrent episodes.
Patients with malignant tumors, active rheumatic immune diseases, or tuberculosis.
Pregnant women, those planning to become pregnant, or breastfeeding women.
Participation in another clinical trial within the last month, anticipated poor compliance, or allergies to any components of the study medication.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified